Related Experiment Video
Updated: Jun 27, 2026
10:51
Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device
Published on: August 30, 2016
22.4K
Engineered E. coli for Long-Term Oral Enzyme Delivery
Xiaoyue Qi1, Fengyuan Zhu1, Ziyong Chang2
1School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Langmuir : the ACS Journal of Surfaces and Colloids
|July 23, 2024
Summary
Engineered bacteria using metal-organic frameworks (MOFs) enhance oral drug delivery. This MOF-exoskeleton approach improves gut retention and biocompatibility for therapeutic applications.
Area of Science:
- Biotechnology
- Materials Science
- Microbiology
Background:
- Intestinal flora possesses natural gut affinity, useful for oral drug delivery.
- Bacteria engineering offers potential for advanced therapeutic strategies.
Purpose of the Study:
- To develop a novel method for engineering bacteria using metal-organic framework (MOF) mineralization for enhanced oral drug delivery.
- To evaluate the efficacy of MOF-engineered Escherichia coli (E. coli) as a carrier for macromolecular therapeutics.
Main Methods:
- Bacteria engineering via MOF mineralization to create an exoskeleton around E. coli.
- Encapsulation of macromolecules within the MOF exoskeleton.
- In-vivo tracking and biocompatibility assessments in gastrointestinal tracts, cells, and animals.
Main Results:
- MOF-engineered E. coli maintained morphology and achieved 60% immobilization efficiency for therapeutic cargoes.
- In-vivo studies showed a 17.9-fold increase in gut retention half-time due to enhanced adhesion to GI mucosa.
- No notable oral toxicity was observed, indicating good biocompatibility.
Conclusions:
- MOF-engineered E. coli provides a versatile platform for on-demand cargo loading with improved gut retention for long-term therapeutic applications.
- This approach demonstrates significant clinical potential for oral drug delivery systems.
More Related Videos
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...